A B S T R A a . Mitochondria1 DNA deletions have been described in the Kearns-Sayre syndrome (KSS) and the Pearson's marrow-pancreas syndrome. In some cases, the same 4 977-bp deletion has been identified in these two very different diseases. Therefore, it is not currently possible to predict the clinical phenotype from the size or location of the deletion. Instead, differential tissue distribution of the deletion has been implicated as one possible determinant of phenotype. In particular, in KSS the deletions have not been detected by Southern blotting in the blood, whereas in Pearson's syndrome they are easily detectable. We describe here an 11-y-old boy with clinically characteristic KSS and a 7.4-kb mitochondrial DNA deletion between nucleotides 7 194 and 14 595. Southern blotting reveals that 75% of the mitochondrial DNA molecules from his peripheral blood have this deletion. This case blurs further the molecular distinction between the KSS and Pearson's marrow-pancreas syndrome, questioning whether tissue distribution is a sufficient explanation for the very different phenotypes of these disorders. (Pediatr Res 31: 557-560,1992) Abbreviations mtDNA, mitochondrial DNA KSS, Kearns-Sayre syndrome nt, nucleotide EBV, Epstein-Barr virus PCR, polymerase chain reaction KSS is a multisystem mitochondrial disorder characterized by juvenile onset, progressive external ophthalmoplegia, and pigmentary retinal degeneration, and frequently accompanied by encephalopathy, ataxia, and heart block (1). In many of these patients, a heteroplasmic mtDNA deletion can be detected (2) (3) (4) (5) . The percentage of normal mtDNA to mtDNA with deletion varies between individuals (3), from tissue to tissue within the same individual (4), and over time (6) . The size of the deletion varies also between affected individuals (1, 3). The relation between severity of disease and size and quantity of mtDNA deletions is not clear. In KSS, a high proportion of mtDNA deletions are found consistently in the most affected tissues, e.g. brain and muscle, whereas low or undetectable amounts are found consistently in some unaffected tissues, e.g. peripheral blood (2, 4-7).
Pearson's marrow-pancreas syndrome is phenotypically an entirely different mitochondrial disorder, with refractory sideroblastic anemia, exocrine pancreatic insufficiency, and liver dysfunction, usually leading to death in infancy (8) . However, the molecular defects are similar to those seen in KSS, with the most common 4 977-bp deletion from nt 8 482 to nt 13 460 being identical in both disorders (8. 9) . The abnormal mtDNA molecules can be detected in most tissues and, in contrast to KSS, are always predominant in the peripheral blood (8) (9) (10) .
In this report we describe a patient with clinically typical KSS, associated with a previously undescribed distribution of deleted mtDNA molecules in this disease. The high proportion of abnormal mtDNA molecules in the peripheral blood of this patient, without associated clinical or laboratory abnormalities, indicates that tissue distribution may not always be a sufficient explanation for the different phenotypes of KSS and Pearson's marrowpancreas syndrome.
MATERIALS AND METHODS
Case report. M.F., born in 1979, was the 3 150-g product of a normal third pregnancy to healthy, unrelated parents. He has an older, healthy brother and a sister who died at 9 d from transposition of the great arteries. Growth delay was noted at 18 mo of age, and his height has remained 3-4 SD below the reference mean, with weight at the 5th percentile. Early psychomotor development was normal, but speech development was delayed. Progressive hearing loss was diagnosed at 6 y of age, when a learning deficit was also noted. At 9 y of age, mild ptosis and ophthalmoplegia, moderate retinal pigmentary degeneration, general muscle weakness, and ataxia with intention tremor were diagnosed. Those features progressively worsened over the next 2 y, and by 11 y of age he was functioning intellectually at the 7-y age level.
Laboratory investigations showed normal electrolytes, mildly elevated serum lactate (2.29 mmol/L, with normal up to 1.78 mmol/L), normal pyruvate (68 pmol/L), an elevated lactate:pyruvate ratio of 33.7, and markedly elevated creatine kinase (8.84 Fkat/L). Plasma amino acids and a glucose tolerance test were normal. A peripheral leukocyte karyotype was normal. A peripheral blood count showed a white blood cell count of 5. except for a symmetrical increase in the T2 signal in the anterior basal ganglia. Electroretinography revealed a low amplitude, a late photopic response, and a barely recordable scotopic response. Muscle biopsy from the left quadriceps showed widely scattered ragged-red fibers on a modified Gomori's trichrome stain, characterized by increased subsarcolemmal mitochondria. When stained with the succinate dehydrogenase reaction, these fibers as well as others reveal increased staining. The percentage of fibers showing increased overall or subsarcolemmal staining was estimated at 3%. Electron microscopy showed scattered fibers containing gigantic mitochondria with crystalline inclusions.
Materials. Restriction enzymes were obtained from Bethesda Research Laboratories (Gaithersburg, MD) and Boehringer Mannheim (Indianapolis, IN). Primers used for the PCR were from Operon Technologies (Alameda, CA). ( L Y~~P ) -~C T P (3000 Ci/mmol) and ( L Y~~S ) -~A T P (800 Ci/mmol) were purchased from New England Nuclear/Dupont (Boston, MA).
Cell lines and tissue samples. Lymphoblastoid cells were immortalized by transformation with EBV (1 1, 12) . For all specimens, informed consent was obtained.
mzDNA analysis by Southern blotting. Patient DNA was extracted from 2 x lo7 EBV-transformed lymphoblastoid cells, 10 mL of whole blood, 20 mL of urine, swabs of cheek mucosa, and scraped-off material from unstained muscle slides by standard techniques (13) . DNA was also extracted from EBV-transformed lymphoblastoid cells from both parents and from peripheral blood of the brother. One pg each of patient and parent DNA obtained from the lymphoblastoid cell lines was used for digestion with different restriction enzymes according to the manufacturer's conditions. The digested samples were electrophoresed through a 0.6% agarose gel and transferred to nylon filters (MSI MagnaNT; Micron Separations Inc., Westboro, MA). The filters were hybridized with 106 c p m / m l of labeled probe overnight at 65"C, washed in 0.1 % SDS/O. I x SSC (3 M NaCl, 0.3 M Na citrate) at 65"C, and exposed for 4 to 6 h to Kodak XAR-5 film with two Lightning Plus intensifying screens at -70°C. The probes were prepared by amplifying 1 pg of normal genomic DNA with the thermostable Tag DNA polymerase (Perkin Elmer Cetus, Nonvalk, CT) and with either primer pairs 5 860-5 879 and 7 492-7 473, flanking the cytochrome oxidase subunit I gene, or primer pairs 10 196-10 2 15 and 12 779-12 760, flanking the NADH dehydrogenase subunits 4 and 4L, in a thermal cycler (Perkin Elmer Cetus) with an initial denaturation step at 98°C for 5 min and 35 three-step cycles of denaturation at 94°C for 30 s, annealing at 54°C for 60 s, and extension at 64°C for 180 s. The probe was labeled with ( C Y~~P ) -~C T P by the multiprime method (Amersham Corp., Arlington Heights, IL). The patterns obtained after Southern blot hybridization were analyzed based on the human mtDNA sequence (14) . The proportion of deleted mtDNA molecules was estimated densitometrically by scanning each lane on the autoradiogram with a Helena EDC densitometer (Helena Laboratories, Beaumont, TX) and then integrating the area under each peak by computer. mtDNA analysis by direct PCR sequencing. Direct sequencing of a double-stranded, undigested PCR fragment was performed using the dideoxy-mediated chain-termination method and (a33)-dATP according to the manufacturer's protocol (Sequenase version 2.0 DNA sequencing kit; United States Biochemical Corp., Cleveland, OH).
RESULTS
Deletion cllaracterization. Patient and parent DNA obtained from the lymphoblastoid cell lines was used for digestion with each of the restriction enzymes PvuII, EcoRI, HindIII, HpaI, BamHI, XbaI, DraI, NcoI, and BgnI. In the patient only, every digest generated abnormal sized fragments in addition to the expected normal sized fragments. With PvuII, which cuts only at position 2 652, an abnormal 9-kb fragment was obtained, indicating a deletion of approximately 7.5 kb. This was confirmed with the other digests, and the breakpoints of the deletion were placed approximately at nt 7 000 and 14 500. Two primers that are 10 066 bp apart at positions 5 860-5 879 and 15 926-15 907 were used for PCR. A 2 660-bp fragment was obtained, which presumably spans the deletion breakpoint. This fragment was first analyzed by digestion with the restriction enzymes PstI, HindIII, AccI, and HaeII, electrophoresis in 1.2% agarose, and visualization of the resulting products by ethidium bromide staining. This localized the deletion breakpoints to nt 6 964-7 198 and 14 370-14 604. To precisely define the breakpoints, the double-stranded, undigested PCR fragment was sequenced directly with a sequencing primer at 6 900-6 919. The sequence corresponded to the normal Cambridge sequence till nt 7 193 and then continued from nt 14 596. This defined the deletion as a 7 402-bp deletion between nt 7 194 and 14 595 (Fig. 1) . Sequence analysis showed the presence of a phenylalanine (TTT) at the 5' end of the deletion in the sequence coding for the cytochrome c oxidase 1 subunit, followed by asparagine (AAT) and a termination signal (AGG). Sequence analysis also revealed the absence of a direct repeat at the breakpoint, but showed the presence of one complete 5-bp and two incomplete 5-and 6-bp inverted repeats, which might form a stable stem loop structure.
Tissue distribution. Using the primers at 5 860-5 879 and 15 926-15 907, the presence of the 2 660-bp deletion fragment was detected by PCR in all available tissues of the patient, e.g. muscle, peripheral blood, urine, and cheek mucosa. The relative proportions of wild-type to deleted mitochondrial chromosomes were assayed by Southern blotting after PvuII digestion and hybridization with a probe external to the deletion at 14 7 15-15 926. Muscle could not be assayed because of the insuficient amount of undegraded DNA available. Autoradiographic data is shown in Figure 2A , and the relative proportions obtained by densitometry are shown in Figure 2B . Interestingly, the proportion of abnormal mtDNA molecules in peripheral blood is 75%.
Family data. Lymphoblastoid cell lines from both parents and peripheral blood from the brother were assayed by PCR for the presence of the deletion as described above. No 2 660-bp deletion fragment was detected.
DISCUSSION
Molecular analysis of this patient with clinically characteristic KSS demonstrates the heteroplasmic presence of a 7 402-bp deletion between nt 7 194 and 14 595. The mitochondrial chromosomes with the deletion, therefore, preserve the promoters of heavy-and light-strand transcription, the 12s and 16s ribosomal RNA genes, and the origins of heavy-and light-strand replication. This is a feature common to nearly all of the described mitochondrial deletions and probably represents the requirement for competent replication. The mechanism of deletion formation in our patient is unclear. Direct repeats of 8-to 13-bp nt were described at the deletion breakpoints of KSS patients and patients with the Pearson's marrow-pancreas syndrome (1 5-17) . The presence of the small, inverted repeats close to the breakpoints of the deletion in our patient are possible sites for the formation of a stem loop structure. Such an intrachromosomal structure, followed by excision of the loop DNA, could lead to the described deletion.
The distribution of the abnormal mitochondrial chromosome in our patient eliminates the previously used molecular distinction between KSS and Pearson's marrow-pancreas syndrome. Previous investigators had shown that the same mtDNA deletion can occur in both of these syndromes (3, 9) . The differential phenotypic expression has generally been ascribed to the different tissue distribution of the deleted mtDNA molecules, in particular the presence of a large proportion of such molecules in the blood of patients with Pearson's syndrome and a tiny proportion in those with KSS (2, (4) (5) (6) (7) (8) (9) (10) . However, in our patient, 75% of the mtDNA molecules in the peripheral blood have a large deletion without any corresponding phenotype. How then do mtDNA deletions exert their effects on cellular function? It has been shown that deleted genomes are transcribed, but not translated (1 8) . In addition, they appear to interfere with the translation of wild-type mitochondrial genomes in the same cell (19) . Just as deleted mtDNA can inhibit the function of normal mtDNA, a small number of defective cells in a tissue such as muscle can interrupt the function of many normal cells. In contrast, hematopoietic cells might not be affected by neighboring cells canying abnormal mitochondrial genomes. Shoubridge et al. (19) showed that the proportion of abnormal to normal mitochondrial genomes in affected muscle cells is about 10 to 1, with the level of normal genomes being similar to that 00 - in unaffected cells. Thus, a minority of cells with large amounts of deleted mtDNA molecules can be responsible for an overall high proportion of deleted mtDNA molecules.
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Although one patient with the Pearson's marrow-pancreas syndrome had essentially no normal mitochondrial genomes in bone marrow and peripheral blood cells (lo), another patient had blood cell proportions of normal to abnormal mitochondrial genomes similar to our patient, but had severe anemia, neutropenia, and thrombocytopenia (8) . Neither tissue distribution nor percentage of the deleted mitochondrial genome can explain the hematologic phenotype. We are thus lefito speculate that either the time of amearance of the abnormal mitochondrial genomes during ontogenesis is important or nuclear factors inteFact with the mitochondrial defect and modulate its expression. Alternatively, the same overall proportion of normal to deleted mtDNA molecules in the peripheral blood can be caused by a small proportion of cells with very high amounts of deleted mtDNA genomes, or by a majority of cells having lower amounts of deleted mtDNA genomes. Periodic reevaluation of the hematologic status and the amount of heteroplasmy in the peripheral blood of our patient, coupled with biochemical and enzymatic investigations, and the analysis of single cells might shed light on the genotype-phenotype relationship.
